Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis.

[1]  E. Kazerooni,et al.  Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort. , 2022, Rheumatology.

[2]  C. Foti,et al.  Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis , 2022, Biomolecules.

[3]  G. Valesini,et al.  Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. , 2021, Clinical and experimental rheumatology.

[4]  C. Denton,et al.  Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis , 2020, Arthritis & rheumatology.

[5]  M. Malaise,et al.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature , 2019, Rheumatology.

[6]  F. Perosa,et al.  CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading , 2019, International journal of molecular sciences.

[7]  G. Valentini,et al.  Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association , 2018, PloS one.

[8]  C. Denton,et al.  SYSTEMIC SCLEROSIS , 2008 .

[9]  G. Valentini,et al.  Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease , 2016, Medicine.

[10]  S. Harari,et al.  Cellular interactions in the pathogenesis of interstitial lung diseases , 2015, European Respiratory Review.

[11]  Sindhu R Johnson,et al.  Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease , 2014, The Journal of Rheumatology.

[12]  X. Corbella,et al.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.

[13]  H. Collard,et al.  Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. , 2014, Chest.

[14]  A. Wells,et al.  Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis , 2014, Arthritis & rheumatology.

[15]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[16]  F. Dammacco,et al.  Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis , 2013, Arthritis Research & Therapy.

[17]  G. Valentini,et al.  Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis , 2013, PloS one.

[18]  M. Bernaudin,et al.  Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. , 2013, The American journal of pathology.

[19]  G. Valentini,et al.  Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? , 2010, Rheumatology.

[20]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[21]  M. Humbert,et al.  Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease , 2009, Annals of the rheumatic diseases.

[22]  V. De Pinto,et al.  Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes1 , 2009, The Journal of Immunology.

[23]  R. Rezzonico,et al.  Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. , 2008, Arthritis and rheumatism.

[24]  M. Gershwin,et al.  The immunobiology of systemic sclerosis. , 2008, Seminars in arthritis and rheumatism.

[25]  M. Humbert,et al.  Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[26]  S. Kaveri,et al.  Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach , 2008, Proteomics.

[27]  J. Dayer,et al.  Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. , 2007, Rheumatology.

[28]  S. Svegliati,et al.  Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. , 2007, Autoimmunity reviews.

[29]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[30]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[31]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[32]  G. Valentini,et al.  Peripheral T lymphocytes from patients with early systemic sclerosis co‐cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin , 2006, Clinical and experimental immunology.

[33]  F. Dammacco,et al.  Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. , 2006, Blood.

[34]  D. Milewicz,et al.  Autoantibodies to Fibrillin-1 Activate Normal Human Fibroblasts in Culture through the TGF-β Pathway to Recapitulate the “Scleroderma Phenotype”1 , 2005, The Journal of Immunology.

[35]  J. Baik,et al.  Human α-enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet's disease , 2003 .

[36]  N. Ronda,et al.  Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. , 2002, Arthritis and rheumatism.

[37]  A. Gabrielli,et al.  Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. , 2002, Arthritis and rheumatism.

[38]  François Tron,et al.  Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[39]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[40]  Orth,et al.  Identification and characterization of autoantibodies against catalase and α‐enolase in patients with primary sclerosing cholangitis , 1998 .

[41]  Zhao,et al.  Catalase and α‐enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD) , 1998 .

[42]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.